Samsung Biologics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 82,273.21 million compared to KRW 21,963.65 million a year ago. Net income was KRW 129,164.03 million compared to KRW 131,773.53 million a year ago. Basic earnings per share from continuing operations was KRW 1,815 compared to KRW 1,992 a year ago. Diluted earnings per share from continuing operations was KRW 1,815 compared to KRW 1,992 a year ago. Basic earnings per share was KRW 1,815 compared to KRW 1,992 a year ago.
For the nine months, sales was KRW 156,698.93 million compared to KRW 86,071.38 million a year ago. Net income was KRW 428,147.03 million compared to KRW 314,271.53 million a year ago. Basic earnings per share from continuing operations was KRW 6,181 compared to KRW 4,750 a year ago. Diluted earnings per share from continuing operations was KRW 6,174 compared to KRW 4,750 a year ago. Basic earnings per share was KRW 6,181 compared to KRW 4,750 a year ago. Diluted earnings per share was KRW 6,174.